Drug Trial Radar · NCT05910801
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Last checked: Nov 20, 2026Latest source record: Nov 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Jan 4, 2024
Primary completion
Dec 30, 2029
Study completion Dec 30, 2030
Sponsor
- Lead sponsor
- Academic and Community Cancer Research UnitedAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Jun 20, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial tests how well tafasitamab, lenalidomide and venetoclax work in treating patients with mantle cell lymphoma that has come back (after a period of improvement) (relapsed) or that has not responded to previous treatment (refractory). Tafasitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Lenalidomide is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (Bcl-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving tafasitamab, lenalidomide and venetoclax together may kill cancer cells more efficiently in patients with relapsed or refractory mantle cell lymphoma.
Conditions
- Recurrent Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma
Interventions
BiopsyProcedure
Undergo biopsy
Biospecimen CollectionProcedure
Undergo blood sample collection
Bone Marrow AspirationProcedure
Undergo bone marrow aspiration
Bone Marrow BiopsyProcedure
Undergo bone marrow biopsy
Computed TomographyProcedure
Undergo CT scan
LenalidomideDrug
Given PO
Lumbar PunctureProcedure
Undergo lumbar puncture
Magnetic Resonance ImagingProcedure
Undergo MRI
Positron Emission TomographyProcedure
Undergo PET/CT scan
TafasitamabBiological
Given IV
VenetoclaxDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rateTime frame: Up to 5 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic in Rochester
Rochester, Minnesota · Recruiting
M D Anderson Cancer Center
Houston, Texas · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.